Vascular Endothelial Growth Factor Family and Receptor Expression in Human Choroidal Neovascular Membranes

2002 ◽  
Vol 64 (1) ◽  
pp. 162-169 ◽  
Author(s):  
Atsushi Otani ◽  
Hitoshi Takagi ◽  
Hideyasu Oh ◽  
Shinji Koyama ◽  
Yuichiro Ogura ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Receptor Expression ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Vascular Endothelial Growth Factor Isoform and Receptor Expression During Compensatory Lung Growth

2010 ◽  
Vol 160 (1) ◽  
pp. 107-113 ◽  
Author(s):  
Tim Jancelewicz ◽  
Erich J. Grethel ◽  
Cheryl J. Chapin ◽  
Matthew S. Clifton ◽  
Kerilyn K. Nobuhara
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Receptor Expression ◽  
Vascular Endothelial ◽  
Lung Growth ◽  
Compensatory Lung Growth ◽  
Endothelial Growth Factor

Differences in vascular endothelial growth factor receptor expression and correlation with the degree of enhancement in medulloblastoma

2014 ◽  
Vol 14 (2) ◽  
pp. 121-128 ◽  
Author(s):  
Shawn L. Hervey-Jumper ◽  
Hugh J. L. Garton ◽  
Darryl Lau ◽  
David Altshuler ◽  
Douglas J. Quint ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Perioperative Complications ◽  
Prognostic Significance ◽  
Growth Factor Receptor ◽  
Extent Of Resection ◽  
Receptor Expression ◽  
Vascular Endothelial ◽  
Significant Difference ◽  
Endothelial Growth Factor

Object Vascular endothelial growth factor (VEGF) is the major proangiogenic factor in many solid tumors. Vascular endothelial growth factor receptor (VEGFR) is expressed in abundance in pediatric patients with medulloblastoma and is associated with tumor metastasis, poor prognosis, and proliferation. Gadolinium enhancement on MRI has been suggested to have prognostic significance for some tumors. The association of VEGF/VEGFR and Gd enhancement in medulloblastoma has never been closely examined. The authors therefore sought to evaluate whether Gd-enhancing medulloblastomas have higher levels of VEGFR and CD31. Outcomes and survival in patients with enhancing and nonenhancing tumors were also compared. Methods A retrospective analysis of patients with enhancing, nonenhancing, and partially enhancing medulloblastomas was performed. Primary end points included risk stratification, extent of resection, and perioperative complications. A cohort of 3 enhancing and 3 nonenhancing tumors was selected for VEGFR and CD31 analysis as well as microvessel density measurements. Results Fifty-eight patients were analyzed, and 20.7% of the medulloblastomas in these patients were nonenhancing. Enhancing medulloblastomas exhibited strong VEGFR1/2 and CD31 expression relative to nonenhancing tumors. There was no significant difference in perioperative complications or patient survival between the 2 groups. Conclusions These results suggest that in patients with medulloblastoma the presence of enhancement on MRI may correlate with increased vascularity and angiogenesis, but does not correlate with worse patient prognosis in the short or long term.

Sign in / Sign up

Export Citation Format

Share Document